Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

112.28 +1.21 (+1.09%)

Official Closing Price Updated: 7:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Abbott Laboratories

< Previous 1 2 3 4 5 6 Next >

Medtronic receives FDA approval for deep brain stimulation system

January 17, 2024

Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS)

Via MarketBeat

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

January 08, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

AbbVie continues shopping spree with biotech buyout

December 12, 2023

While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.

Via MarketBeat

Abbott Laboratories (NYSE: ABT) Highlighted for Surprising Price Action

October 18, 2023

Via Investor Brand Network

Less Is More: Abbott’s Approach to Packaging Innovation

September 11, 2023

Via ACCESSWIRE

Abbott Joins Billion Dollar Roundtable

September 07, 2023

Via ACCESSWIRE

Medtronic: oversold, overextended high yield reversal in play

November 22, 2023

The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance

Via MarketBeat

Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029

November 17, 2023

EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END

Via FinancialNewsMedia

Are These 3 Dividend Aristocrats Undervalued Hidden Gems?

October 25, 2023

Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs.

Via MarketBeat

Abbott Laboratories (NYSE: ABT) is a Leading Gainer in Wednesday Morning Trading

April 19, 2023

Via Investor Brand Network

The Value Deepens for Medtech Stocks: Reversal Imminent

October 23, 2023

MedTech stocks are performing well and supported by pent-up demand, yet share prices are trading at significant and often historical lows.

Via MarketBeat

Oversold and Overextended, Abbott Laboratories is a Great Buy

October 18, 2023

Abbott Laboratories rises on solid results and guidance; the value and dividend are at the best levels in years, and the sell-side is buying.

Via MarketBeat

Lumentum Lights Up on the AI and ML Surge

October 10, 2023

Optical and photonics manufacturer Lumentum Holdings Inc. (NASDAQ: LITE) provides optical components and lasers to data centers, cloud providers, telecoms

Via MarketBeat

Topics Artificial Intelligence

2 Stocks to Benefit from the Aging Population

September 26, 2023

The growth of the aging population is entirely predictable, which makes now an ideal time to consider these two health and wellness stocks

Via MarketBeat

Topics Retirement

A Significant Reversal is in Sight for These 5 Med Tech Companies

August 30, 2023

Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.

Via MarketBeat

5 Good Reasons it's Time to Buy High-Yield Dividend King 3M

August 29, 2023

3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up

Via MarketBeat

Topics Lawsuit

Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher

July 31, 2023

Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans.

Via MarketBeat

Johnson & Johnson's Inflection Point: What it Means for Investors

July 20, 2023

Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories.

Via MarketBeat

Abbott Laboratories Has the Prescription for Higher Share Prices

July 20, 2023

Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating.

Via MarketBeat

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.

Via MarketBeat

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

June 21, 2023

DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.

Via MarketBeat

Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

May 30, 2023

Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning

Via MarketBeat

Can Boston Scientific Set Another Net High?

April 27, 2023

Boston Scientific issued a stellar report and gave favorable guidance, but the stock is having difficulty moving higher and may move sideways in the near term.

Via MarketBeat

Diversified Abbott Laboratories Could Reverse And Move Higher

April 19, 2023

Abbott Laboratories reported a solid quarter driven by gains in the core business that are accelerating as COVID sales decline.

Via MarketBeat

Healthcare Stocks With at Least 30 Years of Dividend Increases

March 14, 2023

Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Via MarketBeat

ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT

March 03, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11

March 01, 2023

Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its

Via MarketBeat

Topics Initial Public Offering

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

February 22, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula

February 17, 2023

New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.

Via MarketBeat

February 14, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Abbott Laboratories (NY:ABT)

Press Releases about Abbott Laboratories

Starting at $3.75/week.

Subscribe Today